Skip to main content
    • Aa
    • Aa

Smith–Magenis syndrome: haploinsufficiency of RAI1 results in altered gene regulation in neurological and metabolic pathways

  • Sarah H. Elsea (a1) (a2) and Stephen R. Williams (a2)

Smith–Magenis syndrome (SMS) is a complex neurobehavioural disorder characterised by intellectual disability, self-injurious behaviours, sleep disturbance, obesity, and craniofacial and skeletal anomalies. Diagnostic strategies are focused towards identification of a 17p11.2 microdeletion encompassing the gene RAI1 (retinoic acid induced 1) or a mutation of RAI1. Molecular evidence shows that most SMS features are due to RAI1 haploinsufficiency, whereas variability and severity are modified by other genes in the 17p11.2 region for 17p11.2 deletion cases. The functional role of RAI1 is not completely understood, but it is probably a transcription factor acting in several different biological pathways that are dysregulated in SMS. Functional studies based on the hypothesis that RAI1 acts through phenotype-specific pathways involving several downstream genes have shown that RAI1 gene dosage is crucial for normal regulation of circadian rhythm, lipid metabolism and neurotransmitter function. Here, we review the clinical and molecular features of SMS and explore more recent studies supporting possible therapeutic strategies for behavioural management.

Corresponding author
*Corresponding author: Sarah H. Elsea, Department of Pediatrics, 1101 E. Marshall Street, 12-018 Sanger Hall, VCU School of Medicine, Richmond, VA 23298, USA. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1M. Shinawi and S.W. Cheung (2008) The array CGH and its clinical applications. Drug Discovery Today 13, 760-770

2P.H. Sudmant (2010) Diversity of human copy number variation and multicopy genes. Science 330, 641-646

3A.C. Smith (1986) Interstitial deletion of (17)(p11.2p11.2) in nine patients. American Journal of Medical Genetics 24, 393-414

4S. Girirajan (2006) Genotype-phenotype correlation in Smith–Magenis syndrome: evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. Genetics in Medicine 8, 417-427

5R.E. Slager (2003) Mutations in RAI1 associated with Smith–Magenis syndrome. Nature Genetics 33, 466-468

6W. Bi (2005) Inactivation of Rai1 in mice recapitulates phenotypes observed in chromosome engineered mouse models for Smith–Magenis syndrome. Human Molecular Genetics 14, 983-995

7P. Carmona-Mora (2010) Functional and cellular characterization of human retinoic acid induced 1 (RAI1) mutations associated with Smith–Magenis syndrome. BMC Molecular Biology 11, 63

8F. Zhang (2010) Identification of uncommon recurrent Potocki–Lupski syndrome-associated duplications and the distribution of rearrangement types and mechanisms in PTLS. American Journal of Human Genetics 86, 462-470

9D.J. Turner (2008) Germline rates of de novo meiotic deletions and duplications causing several genomic disorders. Nature Genetics 40, 90-95

10J.A. Lee , C.M. Carvalho and J.R. Lupski (2007) A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell 131, 1235-1247

12S.H. Elsea and S. Girirajan (2008) Smith–Magenis syndrome. European Journal of Human Genetics 16, 412-421

13R.T. Zori (1993) Clinical, cytogenetic, and molecular evidence for an infant with Smith–Magenis syndrome born from a mother having a mosaic 17p11.2p12 deletion. American Journal of Medical Genetics 47, 504-511

14S.R. Williams (2009) Array comparative genomic hybridisation of 52 subjects with a Smith–Magenis-like phenotype: identification of dosage sensitive loci also associated with schizophrenia, autism, and developmental delay. Journal of Medical Genetics 47, 223-229

17E. Edelman (2007) Gender, genotype, and phenotype differences in Smith–Magenis syndrome: a meta-analysis of 105 cases. Clinical Genetics 71, 540-550

18H.T. Truong (2010) Frameshift mutation hotspot identified in Smith–Magenis syndrome: case report and review of literature. BMC Medical Genetics 11, 142

19B. Burns (2010) Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. Human Molecular Genetics 19, 4026-4042

20A.L. Gropman (2007) New developments in Smith–Magenis syndrome (del 17p11.2). Current Opinion in Neurology 20, 125-134

21M. Di Cicco (2001) Otorhinolaringologic manifestation of Smith–Magenis syndrome. International Journal of Pediatric Otorhinolaryngology 59, 147-150

22F. Greenberg (1996) Multi-disciplinary clinical study of Smith–Magenis syndrome (deletion 17p11.2). American Journal of Medical Genetics 62, 247-254

23N. Liburd (2001) Novel mutations of MYO15A associated with profound deafness in consanguineous families and moderately severe hearing loss in a patient with Smith–Magenis syndrome. Human Genetics 109, 535-541

24R.M. Chen (1996) Ophthalmic manifestations of Smith–Magenis syndrome. Ophthalmology 103, 1084-1091

25B.M. Finucane (1993) Eye abnormalities in the Smith–Magenis contiguous gene deletion syndrome. American Journal of Medical Genetics 45, 443-446

26A.C. Smith , E. Dykens and F. Greenberg (1998) Sleep disturbance in Smith–Magenis syndrome (del 17 p11.2). American Journal of Medical Genetics 81, 186-191

27B.M. Finucane and E.R. Jaeger (1997) Smith–Magenis syndrome. Ophthalmology 104, 732-733

28A.L. Gropman , W.C. Duncan and A.C. Smith (2006) Neurologic and developmental features of the Smith–Magenis syndrome (del 17p11.2). Pediatric Neurology 34, 337-350

29L. Potocki (2003) Variability in clinical phenotype despite common chromosomal deletion in Smith–Magenis syndrome [del(17)(p11.2p11.2)]. Genetics in Medicine 5, 430-434

30L. Potocki (2000) Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. Journal of Medical Genetics 37, 428-433

31H. De Leersnyder (2006) Circadian rhythm disorder in a rare disease: Smith–Magenis syndrome. Molecular and Cellular Endocrinology 252, 88-91

32H. De Leersnyder (2001) Inversion of the circadian rhythm of melatonin in the Smith–Magenis syndrome. Journal of Pediatrics 139, 111-116

33E.A. Boudreau (2009) Review of disrupted sleep patterns in Smith–Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion. American Journal of Medical Genetics A 149A, 1382-1391

34S.S. Park (2002) Structure and evolution of the Smith–Magenis syndrome repeat gene clusters, SMS-REPs. Genome Research 12, 729-738

35K.S. Chen (1997) Homologous recombination of a flanking repeat gene cluster is a mechanism for a common contiguous gene deletion syndrome. Nature Genetics 17, 154-163

36C.J. Shaw and J.R. Lupski (2005) Non-recurrent 17p11.2 deletions are generated by homologous and non-homologous mechanisms. Human Genetics 116, 1-7

37C.J. Shaw , M.A. Withers and J.R. Lupski (2004) Uncommon deletions of the Smith–Magenis syndrome region can be recurrent when alternate low-copy repeats act as homologous recombination substrates. American Journal of Human Genetics 75, 75-81

38P. Stankiewicz (2003) Genome architecture catalyzes nonrecurrent chromosomal rearrangements. American Journal of Human Genetics 72, 1101-1116

40W. Bi (2003) Reciprocal crossovers and a positional preference for strand exchange in recombination events resulting in deletion or duplication of chromosome 17p11.2. American Journal of Human Genetics 73, 1302-1315

41C.J. Shaw , W. Bi and J.R. Lupski (2002) Genetic proof of unequal meiotic crossovers in reciprocal deletion and duplication of 17p11.2. American Journal of Human Genetics 71, 1072-1081

43S. Girirajan (2005) RAI1 variations in Smith–Magenis syndrome patients without 17p11.2 deletions. Journal of Medical Genetics 42, 820-828

44W. Bi (2004) Mutations of RAI1, a PHD-containing protein, in nondeletion patients with Smith–Magenis syndrome. Human Genetics 115, 515-524

45D.E. Treadwell-Deering , M.P. Powell and L. Potocki (2010) Cognitive and behavioral characterization of the Potocki–Lupski syndrome (duplication 17p11.2). Journal of Developmental and Behavioral Pediatrics 31, 137-143

46L. Potocki (2007) Characterization of Potocki–Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a dosage-sensitive critical interval that can convey an autism phenotype. American Journal of Human Genetics 80, 633-649

49K. Walz (2003) Modeling del(17)(p11.2p11.2) and dup(17)(p11.2p11.2) contiguous gene syndromes by chromosome engineering in mice: phenotypic consequences of gene dosage imbalance. Molecular and Cellular Biology 23, 3646-3655

50S. Girirajan and S.H. Elsea (2009) Abnormal maternal behavior, altered sociability, and impaired serotonin metabolism in Rai1-transgenic mice. Mammalian Genome 20, 247-255

51G. Ricard (2010) Phenotypic consequences of copy number variation: insights from Smith–Magenis and Potocki–Lupski syndrome mouse models. PLoS Biology 8, e1000543

52W. Bi (2007) Rai1 deficiency in mice causes learning impairment and motor dysfunction, whereas Rai1 heterozygous mice display minimal behavioral phenotypes. Human Molecular Genetics 16, 1802-1813

53K. Walz (2004) Behavioral characterization of mouse models for Smith–Magenis syndrome and dup(17)(p11.2p11.2). Human Molecular Genetics 13, 367-378

54K. Walz (2006) Rai1 duplication causes physical and behavioral phenotypes in a mouse model of dup(17)(p11.2p11.2). Journal of Clinical Investigation 116, 3035-3041

55S. Girirajan (2008) How much is too much? Phenotypic consequences of Rai1 overexpression in mice. European Journal of Human Genetics 16, 941-954

56J. Molina (2008) Abnormal social behaviors and altered gene expression rates in a mouse model for Potocki–Lupski syndrome. Human Molecular Genetics 17, 2486-2495

57A.D. Capili (2001) Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO Journal 20, 165-177

58Y. Imai (1995) Cloning of a retinoic acid-induced gene, GT1, in the embryonal carcinoma cell line P19: neuron-specific expression in the mouse brain. Brain Research. Molecular Brain Research 31, 1-9

59M. Bienz (2006) The PHD finger, a nuclear protein-interaction domain. Trends in Biochemical Sciences 31, 35-40

60S. Girirajan (2009) A functional network module for Smith–Magenis syndrome. Clinical Genetics 75, 364-374

61F.W. Turek (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308, 1043-1045

62F. Angelucci , S. Brene and A.A. Mathe (2005) BDNF in schizophrenia, depression and corresponding animal models. Molecular Psychiatry 10, 345-352

63L.E. Duncan (2009) Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. Journal of Affective Disorders 115, 215-219

64J.R. Wendland (2007) A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. Neuropsychopharmacology 32, 2543-2551

66J.C. Lauterborn (2009) Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 159, 283-295

67M. Ogier (2007) Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. Journal of Neuroscience 27, 10912-10917

68D.A. Simmons (2009) Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proceedings of the National Academy of Sciences of the United States of America 106, 4906-4911

69S.R. Williams (2010) Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. American Journal of Human Genetics 87, 219-228

70G. Laje (2010) Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 154C, 463-468

71L. Di Lorenzo (2003) Effect of shift work on body mass index: results of a study performed in 319 glucose-tolerant men working in a Southern Italian industry. International Journal of Obesity and Related Metabolic Disorders 27, 1353-1358

72C. Vollmers (2009) Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proceedings of the National Academy of Sciences of the United States of America 106, 21453-21458

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *